HIV treatment and prevention on every 2026 Hawaii Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 8 stand-alone Part D plans in Hawaii cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | AARP Medicare Rx Saver from UHC$0.00/moS5921-381 | Humana Basic Rx Plan$0.40/moS5884-115 | SilverScript Choice$14.70/moS5601-066 | Wellcare Value Script$21.60/moS4802-164 | Wellcare Classic$21.70/moS4802-095 | Humana Value Rx Plan$51.60/moS5884-212 | Humana Premier Rx Plan$90.20/moS5884-179 | AARP Medicare Rx Preferred from UHC$139.20/moS5921-414 |
|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Dovatodolutegravir and lamivudine | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 438%QL 180/30d | Tier 428%QL 180/30d | Tier 435% | Tier 440% | Tier 435% | Tier 430%QL 180/30d | Tier 450%QL 180/30d | Tier 434%QL 180/30d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Julucadolutegravir and rilpivirine | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 438%QL 30/30d | Tier 428%QL 30/30d | Tier 435%QL 30/30d | Tier 440%QL 30/30d | Tier 435%QL 30/30d | Tier 430%QL 30/30d | Tier 450%QL 30/30d | Tier 434%QL 30/30d |
| Tivicaydolutegravir | Tier 525%QL 60/30d | Tier 525%QL 60/30d | Tier 525% | Tier 525% | Tier 525% | Tier 526%QL 60/30d | Tier 533%QL 60/30d | Tier 531%QL 60/30d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.